A Early Phase 1 Clinical Trial To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Hrain Biotechnology Co., Ltd.1 site in 1 country9 target enrollmentOctober 21, 2022

ConditionsB-cell Acute Lymphoblastic Leukemia

InterventionsHuman CD19 Targeted DASH CAR-T Cells Injection

DrugsHuman CD19 Targeted DASH CAR-T Cells Injection

Overview

Phase: Early Phase 1
Intervention: Human CD19 Targeted DASH CAR-T Cells Injection
Conditions: B-cell Acute Lymphoblastic Leukemia
Sponsor: Hrain Biotechnology Co., Ltd.
Enrollment: 9
Locations: 1
Primary Endpoint: Dose limited toxicity (DLT)
Status: Recruiting
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human CD19 targeted DASH CAR-T Cells injection, and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Detailed Description

Subjects with relapsed/refractory B-cell acute lymphoblastic leukemia can participate if all eligibility criteria are met. Tests required to determine eligibility including disease assessments, a physical exam, Electrocardiograph, Computed tomography（CT）/Magnetic Resonance Imaging(MRI)/Positron Emission Tomography（PET）, and blood draws. Subjects will receive preconditioning chemotherapy prior to the infusion of human CD19 targeted DASH CAR-T Cells injection. After the infusion, subjects will be followed for adverse events, pharmacokinetic/pharmacodynamics characteristics, efficacy of human CD19 targeted DASH CAR-T cells. Study procedures may be performed while hospitalized.

Registry

clinicaltrials.gov

Start Date

October 21, 2022

End Date

September 30, 2025

Last Updated

3 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Hrain Biotechnology Co., Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects must meet all of the following criteria to be enrolled:
•18 to 70 years old (including cut-off value), Male and female;
•Expected survival \> 12 weeks;
•ECOG score 0-1;
•Bone marrow examination clearly diagnosed as B-cell acute lymphoblastic leukemia, CD19 positive, and who met one of the following conditions:
•Those who failed to achieve CR after at least 2 courses of standard chemotherapy or had early relapse after complete remission (\<12 months) or late relapse after complete remission (≥ 12 months) and failed to achieve CR after 1 course of standard chemotherapy;
•For Ph+ ALL: in addition to receiving at least 2 courses of standard chemotherapy, at least two TKIs should be treated with no complete remission or relapse after complete remission; (Patients who cannot tolerate TKI therapy or have TKI treatment contraindications or have T315i mutation are excluded);
•Those who relapse after stem cell transplantation are not affected by previous treatments;
•The venous access required for collection can be established and leukapheresis can be carried according to the judgement of investigators;
•Liver, kidney and cardiopulmonary functions meet the following requirements:

Exclusion Criteria

•Any one of the following conditions cannot be selected as a subject：
•Graft-versus-host disease (GVHD), or need to use immunosuppressants after transplantation;
•Patients with hyperleukocytosis (white blood cell count ≥ 50×10\^9/L) or whose disease progressed rapidly according to the investigator's judgment at the time of enrollment and cannot ensure the completion of a complete treatment cycle;
•Malignant tumors other than acute lymphoblastic leukemia within 5 years prior to screening, in addition to adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical resection, ductal carcinoma in situ after radical resection and thyroid cancer after radical resection;
•Subjects with positive Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titer detection higher than the lower limit of the research center can detect; hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; human immunodeficiency virus (HIV) antibody positive; syphilis detection positive;
•Any instability of systemic disease, including but not limited to unstable angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification ≥ III), need drug therapy of severe arrhythmia, liver, kidney, or metabolic disease;
•Active or uncontrollable infection requiring systemic therapy within 14 days prior to enrollment;
•Pregnant or lactating woman, and female subject who plans to have a pregnancy within 1 year after cell transfusion, or male subject whose partner plans to have a pregnancy within 1 year after cell transfusion;
•Received CAR-T treatment or other gene therapies before enrollment;
•Patients with symptoms of central nervous system;

Arms & Interventions

Human CD19 Targeted DASH CAR-T Cells Injection

Single administration：0.5×10\^6 CAR+T, 1.0×10\^7 CAR+T, 2.0×10\^7 CAR+T

Intervention: Human CD19 Targeted DASH CAR-T Cells Injection

Outcomes

Primary Outcomes

Dose limited toxicity (DLT)

Time Frame: 28 days post infusion

Safety Indicators

Secondary Outcomes

Pharmacokinetics parameters - the highest concentration of Human CD19 Targeted DASH CAR-T Cells amplified in peripheral blood after reinfusion(2 years post infusion)
Pharmacokinetics parameters - the time to reach the highest concentration of Human CD19 Targeted DASH CAR-T Cells amplified in peripheral blood after reinfusion(2 years post infusion)
Pharmacokinetics parameters - the 28-day area under the curve of Human CD19 Targeted DASH CAR-T Cells amplified in peripheral blood after reinfusion(2 years post infusion)
Pharmacodynamics characteristics - the detection values of IL-6, IFN-γ, IL-15 cytokines in peripheral blood(2 years post infusion)
Overall response rate (ORR, include CR and CRi) after administration(3 months post infusion)
Duration of remission (DOR) after administration(2 years post infusion)
Overall Survival (OS) after administration(2 years post infusion)